These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30404581)

  • 21. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
    Woitalla D; Kassubek J; Timmermann L; Lauterbach T; Berkels R; Grieger F; Müller T
    Parkinsonism Relat Disord; 2015 Mar; 21(3):199-204. PubMed ID: 25595315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
    Schirinzi T; Imbriani P; D'Elia A; Di Lazzaro G; Mercuri NB; Pisani A
    Clin Neurol Neurosurg; 2017 May; 156():63-65. PubMed ID: 28342306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacology sheet. Transdermal Rotigotine (Neupro)].
    J Pharm Belg; 2010 Jun; (2):49-50. PubMed ID: 20623986
    [No Abstract]   [Full Text] [Related]  

  • 27. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing.
    Hindmarsh J; Hindmarsh S; Lee M
    Clin Drug Investig; 2021 Aug; 41(8):675-683. PubMed ID: 34213758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease.
    Hirano M; Isono C; Sakamoto H; Ueno S; Kusunoki S; Nakamura Y
    Dysphagia; 2015 Aug; 30(4):452-6. PubMed ID: 25966655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Local effects of transdermal treatment with rotigotine].
    Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C
    Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
    Schnitzler A; Leffers KW; Häck HJ
    Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
    Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levomepromazine for nausea and vomiting in advanced cancer.
    Skinner J; Skinner A
    Hosp Med; 1999 Aug; 60(8):568-70. PubMed ID: 10621811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
    Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
    Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.